Kyverna Therapeutics logo
Kyverna Therapeutics
KYTX | NASDAQ
Chart Builder DCF Calculator
$4.76
-$0.29 (-5.74%)
At close: Nov 16, 2026, 4:00 PM ET
$4.76
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Kyverna Therapeutics Company Profile

Company profile explained

Company Profile

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Key Executives

Name Position
Warner Biddle Chief Executive Officer & Director
Gregory Martini Chief Financial Officer
Mayo Pujols Chief Technology Officer
Cara Bauer Chief Human Resources Officer
Christi L. Shaw Executive Chairperson
Dan Maziasz Chief Business Officer
Jessica Serra Head of Investor Relations
Naji Gehchan Chief Medical & Development Officer
Ritesh Srivastava Chief Legal & Compliance Officer
Tom Van Blarcom Senior Vice President & Head of Research
Tracy Rossin Senior Vice President of Corporate Affairs

Latest SEC Filings

Date Type Title
Oct 19, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Sep 24, 2026 8-K Current Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 11, 2026 10-Q Quarterly Report
Aug 11, 2026 8-K Current Report
Jul 29, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Jul 27, 2026 8-K Current Report
Jul 09, 2026 8-K Current Report
Jun 02, 2026 8-K Current Report
May 29, 2026 4 Filing
View All SEC Filings ➞
Kyverna Therapeutics
Kyverna Therapeutics logo
Country United States
IPO Date Feb 9, 2024
Industry Biotechnology
Sector Healthcare
Employees 149
CEO Warner Biddle

Contact Details

5980 Horton Street Emeryville, California 94608 United States

Stock Details

Ticker Symbol KYTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001994702
CUSIP Number 501976104
ISIN Number US5019761049
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.